ARROWHEAD PHARMACEUTICALS IN's ticker is ARWR and the CUSIP is 04280A100. A total of 278 filers reported holding ARROWHEAD PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,360 | -30.3% | 50,588 | -7.6% | 0.00% | – |
| Q2 2023 | $1,952 | +47.7% | 54,726 | +5.2% | 0.00% | – |
| Q1 2023 | $1,322 | -35.8% | 52,020 | +2.5% | 0.00% | – |
| Q4 2022 | $2,059 | -99.9% | 50,760 | -0.2% | 0.00% | – |
| Q3 2022 | $1,682,000 | +3.4% | 50,882 | +10.2% | 0.00% | – |
| Q2 2022 | $1,626,000 | -27.5% | 46,186 | -5.2% | 0.00% | – |
| Q1 2022 | $2,242,000 | -24.3% | 48,741 | +9.1% | 0.00% | – |
| Q4 2021 | $2,961,000 | -0.5% | 44,657 | -6.3% | 0.00% | – |
| Q3 2021 | $2,976,000 | -24.4% | 47,667 | +0.3% | 0.00% | – |
| Q2 2021 | $3,937,000 | +16.4% | 47,539 | -6.8% | 0.00% | – |
| Q1 2021 | $3,382,000 | -20.5% | 50,997 | -8.1% | 0.00% | – |
| Q4 2020 | $4,256,000 | +38.7% | 55,467 | -22.2% | 0.00% | – |
| Q3 2020 | $3,069,000 | +2.1% | 71,276 | +2.4% | 0.00% | – |
| Q2 2020 | $3,007,000 | +73.4% | 69,626 | +15.6% | 0.00% | – |
| Q1 2020 | $1,734,000 | -23.3% | 60,255 | +69.0% | 0.00% | – |
| Q4 2019 | $2,261,000 | +200.7% | 35,652 | +33.5% | 0.00% | – |
| Q3 2019 | $752,000 | -24.0% | 26,698 | -28.4% | 0.00% | – |
| Q2 2019 | $989,000 | +22.6% | 37,304 | -15.2% | 0.00% | – |
| Q1 2019 | $807,000 | +35.9% | 43,994 | -8.1% | 0.00% | – |
| Q4 2018 | $594,000 | -20.8% | 47,863 | +22.4% | 0.00% | – |
| Q3 2018 | $750,000 | +43.4% | 39,109 | +1.7% | 0.00% | – |
| Q2 2018 | $523,000 | +91.6% | 38,468 | +1.5% | 0.00% | – |
| Q1 2018 | $273,000 | +96.4% | 37,900 | 0.0% | 0.00% | – |
| Q4 2017 | $139,000 | +26.4% | 37,900 | +49.2% | 0.00% | – |
| Q3 2017 | $110,000 | +168.3% | 25,400 | 0.0% | 0.00% | – |
| Q2 2017 | $41,000 | -12.8% | 25,400 | -0.7% | 0.00% | – |
| Q1 2017 | $47,000 | +17.5% | 25,567 | 0.0% | 0.00% | – |
| Q4 2016 | $40,000 | -78.7% | 25,567 | 0.0% | 0.00% | – |
| Q3 2016 | $188,000 | +37.2% | 25,567 | -0.5% | 0.00% | – |
| Q2 2016 | $137,000 | – | 25,700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WESTERN FINANCIAL Corp | 820,346 | $62,945,000 | 41.38% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,260,869 | $250,206,000 | 32.27% |
| Aquilo Capital Management, LLC | 365,926 | $28,078,000 | 5.84% |
| L1 Capital Pty Ltd | 298,687 | $23,127,000 | 4.32% |
| First Light Asset Management, LLC | 704,449 | $54,052,000 | 4.00% |
| ACUTA CAPITAL PARTNERS, LLC | 139,000 | $10,665,000 | 2.90% |
| Evolutionary Tree Capital Management, LLC | 48,265 | $3,703,000 | 2.82% |
| Parkman Healthcare Partners LLC | 127,171 | $9,758,000 | 2.50% |
| Capital Impact Advisors, LLC | 88,183 | $6,766,000 | 1.66% |
| Tri Locum Partners LP | 56,003 | $4,297,000 | 1.56% |